Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma

Cancer

Volumn 85, Issue 11, 1999, Pages 2460-2468

  Zelefsky, Michael J ^a   Cowen, Didier ^a   Fuks, Zvi ^a   Shike, Moshe ^a   Burman, Chandra ^a   Jackson, Andrew ^a   Venkatramen, E S ^a   Leibel, Steven A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Complications; Conformal radiotherapy; Dose escalation; Impotence; Proctitis; Prostate carcinoma; Urethral stricture

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROCORTISONE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; GASTROINTESTINAL TOXICITY; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; URETHRA STRICTURE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; IMPOTENCE; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 0033153217     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N     Document Type: Article

References (44)

1. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
2. Hanks GE, Lee WR, Hanlon AL, Kaplan E, Epstein B, Schultheiss T. Conformal technique dose escalation in prostate cancer: improved cancer control with higher doses in patients with pretreatment PSA >10 ng/ml. Int J Radiat Oncol Biol Phys 1996;35:861-8.
3. Pollack A, Zagars GK. External beam radiotherapy dose-response of prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:1011-8.
4. Roach M III, Meehan S, Kroll S, Weill M, Ryu J, Small EJ, Margolis EJ, Presti J, Carroll PC, Phillips TL. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol 1996;156:1719-23.
5. Forman JD, Duclos M, Shamsa F, Porter AT, Orton C. Hyperfractionated conformal radiotherapy in locally advanced prostate cancer: results of a dose escalation study. Int J Radiat Oncol Biol Phys 1996;34:655-62.
6. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988;15:1299-1305.
7. Smit WGJM, Helle PA, van Putten WLJ, Wijnmalalen AJ, Seldenrath JJ, ven Der Werf-Messing BHP. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990;18:23-9.
8. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Mohan R, Mageras GS, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994;21:580-97.
9. Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am 1995;1:142-50.
10. Sandler HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995;33:797-801.
11. Hanks GE, Schultheiss TE, Hunt MA, Epstein B. Factors influencing incidence of acute grade II morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995;31:25-9.
12. Lee WR, Hanks GE, Hanlon A, Schultheiss TE, Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996;35:251-7.
13. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37: 3-11.
14. American Joint Committee on Cancer. Prostate. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J. B. Lippincott, 1992:181-3.
15. Zelefsky MJ, Happersett L, Leibel SA, Burman CM, Schwartz L, Dicker AP, et al. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1997;37:13-9.
16. Zelefsky MJ, Leibel SA, Burman CA, Kutcher GJ, Harrison A, Happersett L, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755-61.
17. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997;49:38-45.
18. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991;21:935-9.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:447-57.
20. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
21. Cox DR. Regression models and life tables. J R Stat Soc 1972;34(Series B):187-220.
22. Taylor JG, Disario JA, Buchi KN. Argon laser for hemorrhagic radiation proctitis: long-term results. Gastrointest Endosc 1993;39:641-4.
23. O'Connor JJ, Strickland KI, Burleson D. Argon laser treatment of radiation proctitis. Gastrointest Endosc 1988;34: 489-94.
24. Jacobs M. YAG laser treatment for radiation proctitis. Gastrointest Endosc 1989;35:355-6.
25. Ahlquist DA, Gostout CJ, Viggiano TR, Pemberton JH. Laser therapy for severe radiation-induced rectal bleeding. Mayo Clin Proc 1986;61:927-31.
26. Rutgeerts P, Van Gompel F, Geboes K, Vantrappen G, Broeckaert L, Coremans G. Long term results of treatment of vascular malformations of the gastrointestinal tract by neodymium Yag laser photocoagulation. Gut 1985;26:586-93.
27. Hunter JG, Burt RW, Becker JM, Lee RG, Dixon JA. Colonic mucosal lesions: evaluation of monopolar electrocautery, argon laser and neodymium: YAG laser. Curr Surg 1984;41: 373-5.
28. Carbatzas C, Spencer GM, Thorpe SM, Sargeant LR, Bown SG. Nd:Yag laser treatment for bleeding from radiation proctitis. Endoscopy 1996;28:497-500.
29. Gilinsky NH, Burns DG, Barbezat GO, Levin W, Myers HS, Marks IN. The natural history of radiation induced proctosigmoiditis: an analysis of 88 patients. Q J Med 1983;205: 40-53.
30. Perez CA, Lee HK, Anasatasios G, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28:811-9.
31. Pistenma DA, Ray GR, Bagshaw MA. The role of megavoltage radiation therapy in the treatment of prostatic carcinoma. Semin Oncol 1976;3:115-22.
32. Taylor WJ, Richardson RG, Haferman MD. Radiation therapy for localized prostate cancer. Cancer 1979;43:1123-7.
33. Del Regato JA. Cancer of the prostate. JAMA 1976;235:1717-30.
34. Shipley WU, Prout GR, Couchman NM, McManus PL, Healey EA, Althausen AF, et al. Radiation therapy for localized prostate cancer: experience at the Massachuseets General Hospital (1973-1981). NCI Monogr 1988;7:67-73.
35. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988; 7:47-60.
36. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stages A2, B carcinoma of the prostate: analysis of RTOG 7706. Int J Radiat Oncol Biol Phys 1988;15:1307-16.
37. Roach M, Chinn DM, Holland J, Clarke M. A pilot survey of sexual function and quality of life following 3D conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1996;35:869-74.
38. Zelefsky MJ, Fuks Z, Wolfe T, Kutcher GJ, Burman C, Ling CC, et al. Three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer: long-term toxicity outcome of the 75.6 and 81 Gy levels of a dose-escalation study. Radiology 1998;209:169-74.
39. Zelefsky MJ, Leibel SA, Kutcher GJ, Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8:107-14.
40. Hartford AC, Niemierko A, Adams JA, Urie MM, Shipley WU. Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. Int J Radiat Oncol Biol Phys 1996;36:721-30.
41. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, et al. Estimation of the incidence of late bladder and rectum complications after high dose (70-78 Gy) conformal radiotherapy for prostate cancer using dose volume histograms. Int J Radiat Oncol Biol Phys 1998;41:83-92.
42. Ling CC, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with multileaf collimation. Int J Radiat Oncol Biol Phys 1996;35:721-30.
43. Mohan R, Zelefsky M, Yang J, Wu Q, Burman C, Leibel S, et al. The potential of optimized intensity modulation to escalate prostate dose to 86.4 Gy. Int J Radiat Oncol Biol Phys 1996;36:197.
44. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984;10:401-9.